Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | AGEN1777 |
Trade Name | |
Synonyms | AGEN-1777|AGEN 1777|BMS-986442|BMS986442|BMS 986442 |
Drug Descriptions |
AGEN1777 (BMS-986442) is a bispecific antibody targeting TIGIT and CD96, which potentially induces enhanced anti-tumor immune response (Cancer Res (2024) 84 (6_Supplement): 3915). |
DrugClasses | TIGIT Antibody 19 |
CAS Registry Number | NA |
NCIT ID | C183161 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AGEN1777 | AGEN1777 | 0 | 1 |
AGEN1777 + Carboplatin + Nivolumab + Paclitaxel | AGEN1777 Carboplatin Nivolumab Paclitaxel | 0 | 1 |
AGEN1777 + Carboplatin + Nivolumab + Pemetrexed Disodium | AGEN1777 Carboplatin Nivolumab Pemetrexed Disodium | 0 | 1 |
AGEN1777 + Docetaxel + Nivolumab | AGEN1777 Docetaxel Nivolumab | 0 | 1 |
AGEN1777 + Nivolumab | AGEN1777 Nivolumab | 0 | 1 |
AGEN1777 + unspecified PD-1 antibody | AGEN1777 unspecified PD-1 antibody | 0 | 1 |